Table 3.

Biomarker expression at index biopsy among 114 women treated with progestin with complex hyperplasia with and without atypia who persisted/progressed (cases) or regressed (controls) within six months.

	Complex (n=73)					Atypia (n=41)
	Cases	Controls				Cases	Controls
	(n=21)	(n=52)				(n=12)	(n=29)
Biomarkers	n (%)	n (%)	OR	95% CI	P-value	n (%)	n (%)	OR	95% CI	P-value
PRA
Low expression	5 (28)	19 (43)	1.0	Reference		6 (55)	7 (30)	1.0	Reference
High expression	13 (72)	25 (57)	2.0	(0.5–8.3)	0.390	5 (45)	16 (70)	0.4	(0.06–2.0)	0.262
PRB
Low expression	6 (32)	15 (34)	1.0	Reference		8 (73)	6 (25)	1.0	Reference
High expression	13 (68)	29 (66)	1.1	(0.3–4.3)	1.000	3 (27)	18 (75)	0.1	(0.01–0.8)	0.011
PRA and PRBa
PRA low, PRB low	5 (28)	13 (30)	1.0	Reference		6 (55)	4 (17)	1.0	Reference
PRA low/PRB high, PRA high/PRB low	1 (6)	8 (18)	0.3	(0.03–3.6)		2 (18)	4 (17)	0.3	(0.03–3.2)
PRA high, PRB high	12 (67)	23 (52)	1.4	(0.4–4.8)	0.464	3 (27)	15 (65)	0.1	(0.02–1.0)	0.059
PTEN
No Loss	6 (30)	27 (52)	1.0	Reference		4 (33)	4 (14)	1.0	Reference
Loss	14 (70)	25 (48)	2.5	0.8–9.2)	0.118	8 (67)	24 (86)	0.3	(0.05–2.3)	0.211
Pax-2
No Loss	3 (14)	3 (6)	1.0	Reference		0 (0)	2 (7)	1.0	Reference
Loss	18 (86)	48 (94)	0.4	(0.05–3.1)	0.348	12 (100)	26 (93)	NE	NE	1.000
Bcl-2
No Loss	13 (62)	23 (46)	1.0	Reference		2 (18)	8 (28)	1.0	Reference
Loss	8 (38)	27 (54)	0.5	(0.2–1.7)	0.300	9 (82)	21 (72)	1.7	(0.3–19.5)	0.696

Data are n(%). Numbers do not add to total due to missing.

Abbreviations: OR=Odds ratio; 95%CI=95% Confidence Interval; NE=Not estimable.

^aAnalysis restricted to women for whom data on both PRA and PRB expression were available.

Odds ratio and exact 95% confidence intervals estimated using epitab in STATA. P-value from Fisher's exact test.